31 July 2019 | News
Alniche and Delhi Pharmaceutical Sciences and Research University (DPSRU) have signed a Memorandum of Understanding for collaboration
image credit- businesswire.com
Alniche Life Sciences, a Delhi based PAN India specialty healthcare company, has launched a Novel healthcare product -Complipro / Ezepro.
Complipro is the first ready-to-use High Protein Oral Supplement to Compensate Intradialytic Amino acid losses. The product distinguishes itself from existing options by combining the right quantity of proteins with the right quality of high biologic value proteins to compensate losses and maintain a positive balance during each dialysis session.
Ezepro is the other variant of the product designed to address the unmet needs of critically ill patients. Ezepro is aimed at avoiding muscle wasting, boosting immune function, thus early recovery in the critical care patients.
CompliPro and Ezepro have a pleasant taste with coffee flavour and are available in ready-to-use single dose can of 150 ml for patient convenience.
Girish Arora (Founder & Managing Director, Alniche Life Sciences) said, that this launch will mark a beginning of Indian Pharma industry focusing on introducing products that are suited for Indian masses.
Alniche and Delhi Pharmaceutical Sciences and Research University (DPSRU) have signed a Memorandum of Understanding for collaboration to develop innovative formulations in the field of Nephrology & Critical care. Under this collaboration, both the partners are working together for three broad areas: Formulation & Development, Concept to Creation and Analysis & Standardisation of differentiated novel Pharmaceuticals. Alniche also instituted two awards (Jwalant & Vijayin) to recognise the young researchers & new start-ups at DPSRU innovation and Incubation Foundation (DIIF) to bring new products, concepts & technologies to the Indian market.